# HUTCHMED unveils next-generation ATTC Platform and key R&D advances

- Link: https://www.directorstalkinterviews.com/hutchmed-unveils-next-generation-attc-platform-and-key-rd-advances/4121223981
- Published: 2025-11-03T07:15:22+00:00
- Author: Amilia Stone

**HUTCHMED (China) Limited** (Nasdaq/LON:HCM; HKEX: 13) has announced key research
and development (R&D) and business updates presented during its R&D Updates event
held on October 31, 2025. The event highlighted HUTCHMED’s progress in advancing
innovative cancer and immunology treatments, including the introduction of its next-
generation Antibody-Targeted Therapy Conjugate (“ATTC”) platform, alongside updates
on late-stage pipeline candidates.

> “Our commitment to advancing innovative therapies drives HUTCHMED’s mission to
> address critical unmet needs in oncology and immunology,” said **Dr. Michael Shi,
> Head of R&D and Chief Medical Officer of HUTCHMED.** “The ATTC platform’s potential
> to redefine precision oncology, combined with our robust pipeline and partnership
> strategy, positions us to deliver potentially transformative cancer and immunology
> treatments to patients around the world.”

### Breakthrough ATTC Platform and Lead Candidate HMPL-A251

The ATTC platform represents potentially a groundbreaking approach to precision 
oncology, integrating monoclonal antibodies with proprietary small-molecule inhibitor
payloads to deliver dual mechanisms of action. The ATTC platform integrates monoclonal
antibodies with proprietary small-molecule inhibitor payloads to deliver dual mechanisms
of action. In contrast to traditional cytotoxin-based antibody-drug conjugates (“
ADC”), ATTCs leverage targeted therapies to achieve synergistic anti-tumor activity
and durable responses, as demonstrated in preclinical models. These conjugates have
shown superior efficacy and safety profiles compared to standalone antibody or small
molecule inhibitor components.

**Overcoming Cancer Challenges with PAM-Targeting Payload:** The first wave of ATTC
candidates focuses on payloads targeting the PI3K/AKT/mTOR (“PAM”) signaling pathway.
The PAM pathway is a critical intracellular network involved in cell growth, survival,
and division. Alterations in the PAM pathway are frequently associated with poor
prognosis and resistance to treatment across various cancers. However, existing 
PAM-targeted drugs face significant limitations, including on-target toxicities 
that restrict dosing, feedback loops that enable pathway reactivation, and insufficient
tumor-specific delivery. The ATTC strategy tries to address these challenges by 
enhancing targeted delivery of PAM inhibitors directly to tumor cells, maximizing
therapeutic benefit while minimizing systemic exposure.

**HUTCHMED’s Lead ATTC Candidate, HMPL-A251:** HMPL-A251 is a PAM-HER2 ATTC consisting
of a highly selective and potent PI3K/PIKK inhibitor payload conjugated to a humanized
anti-HER2 IgG1 antibody via a cleavable linker. Preclinical data for HMPL-A251 was
recently presented at the 2025 AACR-NCI-EORTC International Conference on Molecular
Targets and Cancer Therapeutics. _In vitro_, the PI3K/PIKK inhibitor payload exhibited
high selectivity, potency, and robust anti-tumor activity across a diverse panel
of tumor cell lines. HMPL-A251 demonstrated HER2-dependent antitumor activity, with
potent inhibition of HER2-positive tumor cell growth regardless of PAM pathway alterations,
and moderately reduced activity in HER2-low, PAM-altered lines. Notably, HMPL-A251
exhibited a strong bystander effect, impacting HER2-null cells when co-cultured 
with HER2-positive cells. _In vivo_ evaluations showed superior anti-tumor efficacy
and tolerability compared to the naked antibody and payload administered separately.
When benchmarked against trastuzumab deruxtecan (T‑-DXd), a leading HER2-directed
ADC, HMPL-A251 achieved comparable or superior efficacy at equivalent doses in most
models tested. Furthermore, payload-related toxicities are anticipated to be improved,
with plasma exposure of the free payload being significantly lower than that of 
HMPL-A251.

Encouraged by these promising preclinical results in both HER2-positive and HER2-
low models, with or without PAM alterations, HUTCHMED plans to advance HMPL-A251
into clinical development starting in late 2025 using a data-driven strategy. Initial
studies will evaluate the candidate across various cancer types with diverse HER2
and PAM alteration statuses.

**Adaptable Payload and Antibody Design Unlocks Versatile Mechanisms:** Beyond HER2-
targeted antibodies, HUTCHMED aims to explore a broader range of antibody selections
that synergize with the payload’s signaling pathways, leveraging the antibody as
a delivery vehicle to enhance combination effects. Payload options are also adaptive,
targeting a wide array of signaling pathways, positioning ATTCs as a versatile tool
in overcoming resistance and improving treatment outcomes. Additionally, ATTC shows
potential for combination with chemotherapy-based frontline standard-of-care treatments
or as a chemotherapy-free adjuvant for long-term use, enhancing its possible application
as combination therapy in early-line settings. Successful development of multiple
ATTC molecules is expected to lead to collaboration and licensing opportunities 
in the future. Initial responses from potential partners are very positive.

### Significant Progress from Late-stage Programs

In addition to the ATTC platform, the R&D Updates featured updates on some of the
late-stage programs:

·      **Fruquintinib FRUSICA-2 Study:** Data from the Phase III trial of fruquintinib
in combination with sintilimab for second-line renal cell carcinoma was presented
at ESMO Congress 2025. The combination achieved a progression-free survival (PFS)
of 22.2 months versus 6.9 months with standard-of-care axitinib or everolimus (hazard
ratio [HR]: 0.37; p<0.0001). The objective response rate more than doubled to 60.5%
versus 24.3%, with a median duration of response of 23.7 months compared to 11.3
months.

·      **Savolitinib Registration Studies:** Recruitment has been completed for 
the SANOVO China Phase III study in first-line EGFR-mutated non-small cell lung 
cancer (“NSCLC”) with MET overexpression. Recruitment for the SAFFRON global Phase
III study for second-line EGFR-mutated NSCLC patients with MET amplification or 
overexpression is progressing well, with enrollment completion expected in late 
2025.

·      **Surufatinib for Pancreatic Cancer:** The Phase II/III study of surufatinib
combined with Hengrui’s camrelizumab (a PD-1 antibody), nab-paclitaxel, and gemcitabine
for first-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) remains
on track. Results from the Phase II portion will be presented at an upcoming scientific
conference.

·      **Sovleplenib for ITP and wAIHA:** Preparations for the resubmission of the
new drug application for second-line immune thrombocytopenia (ITP) are progressing
as outlined in the 2025 interim report, with resubmission planned for the second
quarter of 2026. The ESLIM-02 study in second-line warm autoimmune hemolytic anemia(
wAIHA) has completed enrollment, with topline results expected in early 2026.

·      **Fanregratinib in China:** Recruitment for the registrational Phase II study
in patients with advanced intrahepatic cholangiocarcinoma (IHCC) in China has been
completed, with new drug application submission preparation underway for the first
half of 2026.

[pre251031](https://www.directorstalkinterviews.com/wp-content/uploads/2025/11/pre251031.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2025/11/pre251031.pdf)

Share on:
